Targeting JAK/STAT signaling: ruxolitinib cream in the management of concurrent vitiligo and discoid lupus erythematosus. Dermatology Reports, [S. l.], 2025. DOI: 10.4081/dr.2025.10458. Disponível em: https://journals.pagepress.org/dr/article/view/10458. Acesso em: 9 oct. 2025.